Boehringer Ingelheim Lilly present posthoc analysis data from linagliptin clinical trials at EASD 2013

Boehringer Ingelheim and Eli Lilly and Company today announced results from two posthoc pooled analyses of data from placebocontrolled clinical trials which examined the safety of the dipeptidyl pepti…
Read the full story: Bioportfolio Latest News